Compare iShares MSCI China ETF (MCHI) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Revvity Inc — how do they compare? iShares MSCI China ETF trades at $53.9, while Revvity Inc trades at $110.1 (market cap $11.87B). The key difference: Revvity Inc pays a 0.26% dividend while iShares MSCI China ETF pays none, and Revvity Inc is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.
| MCHI | RVTY | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $66.99 | $117.75 |
52-Week Low | $50.48 | $82.26 |
Market Cap | — | $11.87B |
Enterprise Value | — | $14.36B |
Dividend Yield | — | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI trades at $54.08, up 2.13% with a bullish technical signal from moving averages. The stock shows neutral momentum oscillators with RSI at 68.39 suggesting mild overbought conditions. Recent news highlights China's focus on AI infrastructure investment and export controls on technology sectors, creating both opportunities and regulatory uncertainties for China-focused ETFs.
The outlook remains cautiously optimistic given China's economic stabilization efforts and AI sector growth, though geopolitical tensions and value trap concerns present significant risks. Wall Street sentiment appears mixed with some analysts highlighting structural headwinds while others see potential in the technology sector rebound.
RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.
The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
